Induction and reversal of myotonic dystrophy type 1 pre-mRNA splicing defects by small molecules. - Wikidata - wikimedia - TriplyDB

Induction and reversal of myotonic dystrophy type 1 pre-mRNA splicing defects by small molecules.

Induction and reversal of myotonic dystrophy type 1 pre-mRNA splicing defects by small molecules.

http://www.wikidata.org/entity/Q34786164

about

Studying a Drug-like, RNA-Focused Small Molecule Library Identifies Compounds That Inhibit RNA Toxicity in Myotonic Dystrophy Small Molecule Inhibition of miR-544 Biogenesis Disrupts Adaptive Responses to Hypoxia by Modulating ATM-mTOR Signaling Stacking in RNA: NMR of Four Tetramers Benchmark Molecular Dynamics Structure of the myotonic dystrophy type 2 RNA and designed small molecules that reduce toxicity.Computational investigation of RNA CUG repeats responsible for myotonic dystrophy 1 Autoregulation of MBNL1 function by exon 1 exclusion from MBNL1 transcript.Targeting toxic RNAs that cause myotonic dystrophy type 1 (DM1) with a bisamidinium inhibitor.Methods to enable the design of bioactive small molecules targeting RNA.Lomofungin and dilomofungin: inhibitors of MBNL1-CUG RNA binding with distinct cellular effects.RNA-protein interactions in unstable microsatellite diseases.MBNL proteins and their target RNAs, interaction and splicing regulation.Splicing landscape of the eight collaborative cross founder strains.Short antisense-locked nucleic acids (all-LNAs) correct alternative splicing abnormalities in myotonic dystrophy.RNA Structures as Mediators of Neurological Diseases and as Drug Targets.On the Applicability of Elastic Network Models for the Study of RNA CUG Trinucleotide Repeat Overexpansion.Precise small-molecule recognition of a toxic CUG RNA repeat expansion.In silico discovery of substituted pyrido[2,3-d]pyrimidines and pentamidine-like compounds with biological activity in myotonic dystrophy models.Splicing misregulation of SCN5A contributes to cardiac-conduction delay and heart arrhythmia in myotonic dystrophy.A Potent Inhibitor of Protein Sequestration by Expanded Triplet (CUG) Repeats that Shows Phenotypic Improvements in a Drosophila Model of Myotonic Dystrophy.Rational design of chemical genetic probes of RNA function and lead therapeutics targeting repeating transcripts.Developmental insights into the pathology of and therapeutic strategies for DM1: Back to the basics.The Emerging Role of RNA as a Therapeutic Target for Small Molecules.Development of pharmacophore models for small molecules targeting RNA: Application to the RNA repeat expansion in myotonic dystrophy type 1.RNA mis-splicing in disease.Hypo- and Hyper-Assembly Diseases of RNA-Protein Complexes.Dynamic changes of nuclear RNA foci in proliferating DM1 cells.Development of a Drosophila melanogaster spliceosensor system for in vivo high-throughput screening in myotonic dystrophy type 1.Hybrid splicing minigene and antisense oligonucleotides as efficient tools to determine functional protein/RNA interactions.Design of a "Mini" Nucleic Acid Probe for Cooperative Binding of an RNA-Repeated Transcript Associated with Myotonic Dystrophy Type 1.Using Genome Sequence to Enable the Design of Medicines and Chemical Probes.Design of Bivalent Nucleic Acid Ligands for Recognition of RNA-Repeated Expansion Associated with Huntington's Disease.[Deregulation of pre-messenger RNA splicing and rare diseases].Daunorubicin reduces MBNL1 sequestration caused by CUG-repeat expansion and rescues cardiac dysfunctions in a Drosophila model of myotonic dystrophy.Morpholino Antisense Oligomers as a Potential Therapeutic Option for the Correction of Alternative Splicing in PMD, SPG2, and HEMS.Alteration of RNA Splicing by Small-Molecule Inhibitors of the Interaction between NHP2L1 and U4 Insights into the development of chemical probes for RNA

P2860

Q28830592-C7AED469-C8B9-4076-B8B7-76CDA3D0596A Q28833656-E9D20671-B870-4541-91DE-D64CD12E1D83 Q29299984-2C585B49-3311-471E-AD7C-8C46A5AD7D19 Q30573524-15AFBBA4-504D-41CE-B8E5-1358979A7AA0 Q30668605-2C6284EC-91C6-4D19-828F-50956F33CF89 Q33557647-BB01602C-EA2E-46BA-A544-DB9307911C8C Q33588831-88F8B8D1-B924-4AAE-82C5-45E459510CDD Q33609375-18F6E525-F361-498D-9A06-D712B36EF7F6 Q33698593-4592EDA0-786B-42BD-8B7A-58E45FF7E828 Q34243144-B99D2FA8-6334-41AF-8591-C10E4724CD90 Q34248811-4E300F59-0D1F-4E41-B841-6516C6E89925 Q35061346-3E1E97AD-89E9-498D-9836-704E9BBBD47E Q35237068-938F7C4B-BDC5-4090-AC2D-8F9FDA59D46E Q35868044-B8635427-F0AA-42AB-A3EE-32A9B2FA2CA2 Q35968544-45C83E20-F398-4F2A-9613-3F675C963695 Q36219835-6216936E-0D36-4C90-A01E-D5C10457D0EA Q36392989-A695C22A-F973-4D70-9273-7306FB25E212 Q36796408-98941F7C-A9E6-4C25-9A63-AA3BABC79518 Q37358384-2AEBA578-0B54-4D5E-8EDC-765828C50C06 Q37360833-3782FA4D-CC41-4C8E-A625-20F17D5A5DF3 Q38287631-1187F4E1-09F4-45DB-BD0F-B90AE957BE17 Q38410949-EE5A0A8A-E8E2-4A84-90AF-D797D2DEC1C3 Q38434922-509EC4B1-6383-4F85-A465-0A4401FA0BD2 Q38642996-600886C0-9868-4D26-B2D3-D2A96C273CBE Q38855284-FCFB75CA-C84C-4A88-8E94-A62392AF1D16 Q40902020-352027B6-F248-47A9-A140-4D15DFA37236 Q41997886-A018E68A-0150-4A9E-9960-BDCBAF7493CF Q47158430-5C79E525-DF54-45CE-86A0-789DD0A90870 Q48242863-ABB2AF20-AB8B-4EA5-9A29-78C8C855428F Q48263612-41DD8425-C1B7-48CE-8607-4E77B7F2BDBE Q51737120-1F8FD6BA-91F3-4779-AA4C-D2B2E5367209 Q53968476-20A7F0E1-790E-44A7-BCF0-E55B126ED439 Q54967674-8F8E39E4-8075-402C-8A99-FA2DF9728475 Q55560238-B9D08631-0F48-4C34-899D-E5A27E0E8D7B Q57810693-87D44333-022A-476F-9E4D-C6C39D69EA57 Q58794879-A2BDE234-459E-4756-B327-8C706C9003E6

P2860

Induction and reversal of myotonic dystrophy type 1 pre-mRNA splicing defects by small molecules.

http://www.wikidata.org/entity/Q34786164

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Induction and reversal of myot ...... ng defects by small molecules.

@ast

Induction and reversal of myot ...... ng defects by small molecules.

@en

Induction and reversal of myot ...... ng defects by small molecules.

@nl

type

label

Induction and reversal of myot ...... ng defects by small molecules.

@ast

Induction and reversal of myot ...... ng defects by small molecules.

@en

Induction and reversal of myot ...... ng defects by small molecules.

@nl

prefLabel

Induction and reversal of myot ...... ng defects by small molecules.

@ast

Induction and reversal of myot ...... ng defects by small molecules.

@en

Induction and reversal of myot ...... ng defects by small molecules.

@nl

P1433

Q34786164-D94CDCAB-565B-4CA6-9A5D-152B8AAD7AC4

P1476

Q34786164-C3AA56B9-8221-4230-BDF6-7F43DF06A41B

P2093

Q34786164-02D37BAA-2426-47D7-A255-C9304BA873F7

Q34786164-05758244-1ACA-465E-9D46-0255662AC277

Q34786164-38ECD5A3-46D3-40F1-964B-15F2F0ADBBE2

Q34786164-67958D37-D07F-4F54-A78A-507A397C95B8

Q34786164-70FABF4D-A249-4E66-94ED-7D408B5CDB67

Q34786164-8C33EE52-C483-4965-96F5-3027A91B7660

Q34786164-8FF5FA04-9A13-4E2C-AE88-1F2EAAE6F424

Q34786164-A09CA630-7EF8-4272-B2F5-A83BF6ABC97F

Q34786164-B86FBF14-BD0F-4537-B356-2EF30F22C77A

Q34786164-D5B43B17-69DA-41B5-AD07-F21C112AA308

P2860

Q34786164-07EDCB84-DF74-4BAE-9E33-7890CB4D3E07

Q34786164-08B4C5A7-863E-404B-870A-0C5386925837

Q34786164-09DA29CF-C0BC-48FA-A152-852A90E39D3B

Q34786164-0DE4A0FA-F0A3-4651-AC78-F7C7078B1915

Q34786164-13ADFACB-D021-4EC2-932C-99E107FE7835

Q34786164-1D49D576-EE26-45BA-95F3-A01F003E53E5

Q34786164-1E866A65-3E8B-49E6-87A8-B8DBDD7CF990

Q34786164-231E337F-7CAB-4195-ADE7-944F6E4F5E06

Q34786164-23707118-B598-4493-A3FA-82C93144234A

Q34786164-266B888B-D5D8-49E1-9B00-AA5F8E8D77FC

P2888

Q34786164-D1661E74-9608-4B96-A71D-2E07F1072B39

P304

Q34786164-D9D91A43-5BF4-49C5-93EA-A9B946CE657E

P31

Q34786164-D8C29077-BEEE-45CA-A67F-EDA2C234AA9A

P356

Q34786164-A8254673-1B00-45F1-8A8A-9C7368C9EDA2

P407

Q34786164-8C27F0C9-FEEA-419E-A225-05E89FA21540

P478

Q34786164-ECF37EBC-26D1-48EE-8DE5-E4532C2D16DF

P50

Q34786164-18BC78B3-FF83-41EB-8809-2EFDEE756E27

Q34786164-4DABCEAC-37C8-4B50-A1C5-842229606065

Q34786164-4DAEE861-87FC-4C8B-AF22-99B1ABFC93E3

Q34786164-71CB0A3F-9E40-4C20-A91D-448DC2CA8D08

Q34786164-A9EB1390-E267-4A4F-8A33-4B9CBB845520

P577

Q34786164-572567B8-553D-4C55-BBBB-D6596CB94D7B

P5875

Q34786164-C47ECFB8-00B7-4E1F-88FD-1A795FF6ED0E

P6179

Q34786164-DFD152D8-B2BB-47E1-87E0-9696ADA0B8F0

P698

Q34786164-A85F4427-A87D-4FBC-9BF4-A67540A0C7E2

P932

Q34786164-1D2EC0CA-781C-4DE0-85AE-A49B0127D6FA

P356

P1433

Nature Communications

P1476

Induction and reversal of myot ...... ing defects by small molecules

@en

P2093

Catherine Z Chen

http://www.w3.org/2001/XMLSchema#string

Charles A Thornton

http://www.w3.org/2001/XMLSchema#string

Chris P Austin

http://www.w3.org/2001/XMLSchema#string

HaJeung Park

http://www.w3.org/2001/XMLSchema#string

Ilyas Yildirim

http://www.w3.org/2001/XMLSchema#string

Jessica L Childs-Disney

http://www.w3.org/2001/XMLSchema#string

Juan J Marugan

http://www.w3.org/2001/XMLSchema#string

Krzysztof Sobczak

http://www.w3.org/2001/XMLSchema#string

Matthew D Disney

http://www.w3.org/2001/XMLSchema#string

Samarjit Patnaik

http://www.w3.org/2001/XMLSchema#string

P2860

Muscleblind proteins regulate alternative splicing

The splicing regulator Sam68 binds to a novel exonic splicing silencer and functions in SMN2 alternative splicing in spinal muscular atrophy

Muscleblind-like 2-mediated alternative splicing in the developing brain and dysregulation in myotonic dystrophy

The RNA-binding protein Sam68 modulates the alternative splicing of Bcl-x

Structural insights into RNA recognition by the alternative-splicing regulator muscleblind-like MBNL1

NMR spectroscopy and molecular dynamics simulation of r(CCGCUGCGG)₂ reveal a dynamic UU internal loop found in myotonic dystrophy type 1.

Myotonic Dystrophy Type 1 RNA Crystal Structures Reveal Heterogeneous 1 × 1 Nucleotide UU Internal Loop Conformations

Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9

MBNL1 is the primary determinant of focus formation and aberrant insulin receptor splicing in DM1

Pre-mRNA splicing and human disease

P2888

P304

2044

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NCOMMS3044

http://www.w3.org/2001/XMLSchema#string

P407

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

George C. Schatz

Ewa Stepniak-Konieczna

P577

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

242652752

http://www.w3.org/2001/XMLSchema#string

P6179

1018823268

http://www.w3.org/2001/XMLSchema#string

P698

23806903

http://www.w3.org/2001/XMLSchema#string

P932

3710115

http://www.w3.org/2001/XMLSchema#string